Home > Rheumatology > EULAR 2020 > Osteoporosis and Osteoarthritis > Positive effect denosumab on fall risk

Positive effect denosumab on fall risk

Presented By
Dr Yasser El Miedany, Darent Valley Hospital, United Kingdom
EULAR 2020
Osteoporosis is strongly associated with skeletal muscle dysfunction [1]. A recent study found that treatment with denosumab improved physical performances, grip strength, and gait speed outcomes, and thus appears to reduce the risk of falling for osteoporosis patients. Heparan-sulphate proteoglycans are abundant in skeletal muscles and may represent a target for receptor activator of nuclear factor-kB (RANKL) inhibitor, such as denosumab. Thus, Dr Yasser El Miedany (Darent Valley Hospital, United Kingdom) and colleagues set out to investigate the effect of denosumab on fall risk, physical performance, grip strength, and gait speed, and whether a relationship exists with bone mineral density (BMD) [1]. This was done by assessing 127 osteoporotic patients at the start of treatment with denosumab and again after 5 years. The investigators assessed baseline BMD (measured by dual X-ray absorptiometry), the patients’ osteoporosis bone profile by means of a blo...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on